Summit Therapeutics plc (SMMT): Price and Financial Metrics

Summit Therapeutics plc (SMMT): $5.38

0.20 (+3.86%)

POWR Rating

Component Grades













SMMT Stock Summary

  • The ratio of debt to operating expenses for Summit Therapeutics plc is higher than it is for about only 0.42% of US stocks.
  • With a year-over-year growth in debt of -100%, Summit Therapeutics plc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Summit Therapeutics plc comes in at 1,893.29%, a number that bests 99.56% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics plc, a group of peers worth examining would be VYGR, ANAB, CRBP, CARA, and NVAX.
  • Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $5.38 52-week high $12.30
Prev. close $5.18 52-week low $3.15
Day low $5.21 Volume 981,800
Day high $6.26 Avg. volume 225,931
50-day MA $7.33 Dividend yield N/A
200-day MA $6.66 Market Cap 523.92M

Summit Therapeutics plc (SMMT) Company Bio

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.

SMMT Latest News Stream

Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream

Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics Provides Update on Ri-CoDIFy Trials

Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study.

Intrado Digital Media | August 11, 2021

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021

Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the second quarter and six months ended June 30, 2021.

Intrado Digital Media | August 11, 2021

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

Yahoo | August 5, 2021

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of ActionCambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Two ePosters bring increased awareness and understanding of the significance of data generated using shotgun metagenomi

Yahoo | July 12, 2021

Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster

Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the Company) today announced that members of our scientific team will present breakthrough research updates at the 31 st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will be held virtually July 9 12. Our three posters to be presented are as follows, one of which was designated as a Top Rated ePoster by the ECCMID conference:

Intrado Digital Media | July 1, 2021

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo -33.58%
3-mo -19.46%
6-mo -0.92%
1-year 56.85%
3-year 143.44%
5-year -38.37%
YTD 14.47%
2020 193.75%
2019 39.13%
2018 -89.62%
2017 29.44%
2016 -25.57%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.3721 seconds.